Rasio rega marang prakiraan pendapatan Burning Rock Biotech (BNR)

Geopolitical tensions between Washington and Beijing are restricting the cross-border exchange of biodata, creating risks for Burning Rock Biotech (BNR). The business's forward P/S reflects valuation dynamics relative to expected revenue, where the value 1.60 serves as the baseline trend indicator. Profit growth depends on sequencing automation; however, government pressure on test pricing in China significantly limits the company's pricing power.

Burning Rock Biotech's strategic alliances in liquid biopsy directly drive the dynamics of the forward P/S valuation, reflecting market expectations for the commercialization of joint diagnostic projects. This indicator compares current market capitalization with expected annual revenue, allowing investors to assess the premium for future sales growth and differentiate the long-term fundamental trend from short-term price volatility.